S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:DBVT

DBV Technologies (DBVT) Stock Price, News & Analysis

$0.76
-0.02 (-2.57%)
(As of 03/27/2024 ET)
Today's Range
$0.73
$0.82
50-Day Range
$0.76
$0.92
52-Week Range
$0.65
$2.37
Volume
124,626 shs
Average Volume
62,349 shs
Market Capitalization
$145.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

DBV Technologies MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
560.7% Upside
$5.00 Price Target
Short Interest
Healthy
0.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.16mentions of DBV Technologies in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$1,624 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.88) to ($0.14) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.41 out of 5 stars

Medical Sector

323rd out of 939 stocks

Biological Products, Except Diagnostic Industry

47th out of 157 stocks

DBVT stock logo

About DBV Technologies Stock (NASDAQ:DBVT)

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBVT Stock Price History

DBVT Stock News Headlines

DBVT DBV Technologies S.A.
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)
DBV Technologies S.A. ADR
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
See More Headlines
Receive DBVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:DBVT
Employees
104
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$10.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+560.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-72,730,000.00
Net Margins
-461.32%
Pretax Margin
-462.35%

Debt

Sales & Book Value

Annual Sales
$15.73 million
Book Value
$0.73 per share

Miscellaneous

Free Float
191,707,000
Market Cap
$145.96 million
Optionable
Optionable
Beta
0.76
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Daniel Tassé (Age 64)
    CEO & Director
    Comp: $1.21M
  • Dr. Pharis Mohideen (Age 59)
    Chief Medical Officer
    Comp: $725.12k
  • Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A. (Age 55)
    CFO & Principal Accounting Officer
  • Dr. Kevin P. Malobisky M.S.
    Ph.D., R.A.C., Chief Operations Officer
  • Ms. Michele F. Robertson
    Chief Legal Officer
  • Ms. Caroline Daniere (Age 49)
    Chief Human Resources Officer & Chief of Staff
  • Dr. Wence Agbotounou
    Chief Clinical Trial Officer & Senior VP
  • Mr. Edward P. Jordan M.B.A. (Age 56)
    Senior Vice President of Commercial Operations North America
  • Alan Kerr
    Senior VP & Head of Global Regulatory Affairs
  • Mr. Pascal Wotling
    Chief External Manufacturing & Supply Chain Officer

DBVT Stock Analysis - Frequently Asked Questions

Should I buy or sell DBV Technologies stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DBVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DBVT, but not buy additional shares or sell existing shares.
View DBVT analyst ratings
or view top-rated stocks.

What is DBV Technologies' stock price target for 2024?

3 brokers have issued twelve-month target prices for DBV Technologies' stock. Their DBVT share price targets range from $1.00 to $10.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 560.7% from the stock's current price.
View analysts price targets for DBVT
or view top-rated stocks among Wall Street analysts.

How have DBVT shares performed in 2024?

DBV Technologies' stock was trading at $0.9528 on January 1st, 2024. Since then, DBVT shares have decreased by 20.6% and is now trading at $0.7568.
View the best growth stocks for 2024 here
.

Are investors shorting DBV Technologies?

DBV Technologies saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 548,100 shares, a drop of 6.2% from the February 29th total of 584,500 shares. Based on an average daily volume of 67,900 shares, the days-to-cover ratio is presently 8.1 days.
View DBV Technologies' Short Interest
.

When is DBV Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our DBVT earnings forecast
.

How were DBV Technologies' earnings last quarter?

DBV Technologies S.A. (NASDAQ:DBVT) issued its earnings results on Thursday, March, 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.10. The company earned $8.88 million during the quarter, compared to analysts' expectations of $1.10 million. DBV Technologies had a negative trailing twelve-month return on equity of 46.33% and a negative net margin of 461.32%. During the same period in the previous year, the business posted ($0.23) EPS.

What other stocks do shareholders of DBV Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO).

Who are DBV Technologies' major shareholders?

DBV Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Braidwell LP (4.07%), Boxer Capital LLC (0.26%), Citadel Advisors LLC (0.08%), Cowen AND Company LLC (0.03%), Goldman Sachs Group Inc. (0.02%) and Goldman Sachs Group Inc. (0.02%). Insiders that own company stock include Adora Ndu, Daniel B Soland, Pharis Mohideen and Timothy E Morris.
View institutional ownership trends
.

How do I buy shares of DBV Technologies?

Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DBVT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners